Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial.

Bernard-Tessier A, Jeannot E, Guenat D, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bièche I, Pierga JY, Buecher B, Meurisse A, François É, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S.

Clin Cancer Res. 2018 Nov 30. doi: 10.1158/1078-0432.CCR-18-2984. [Epub ahead of print]

PMID:
30504426
2.

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions.

Decraene C, Bortolini Silveira A, Michel M, Bidard FC, Pierga JY, Stern MH, Proudhon C.

J Vis Exp. 2018 Sep 25;(139). doi: 10.3791/58051.

PMID:
30320738
3.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.

Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.

PMID:
30054279
4.

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.

Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, Pierga JY, Bidard FC.

Nat Rev Clin Oncol. 2018 Oct;15(10):639-650. doi: 10.1038/s41571-018-0074-3. Review.

PMID:
30050094
5.

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.

Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching PA, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY.

Ann Oncol. 2018 Aug 1;29(8):1777-1783. doi: 10.1093/annonc/mdy211.

PMID:
29893791
6.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
7.

Circulating tumor DNA detection in hepatocellular carcinoma.

Cabel L, Proudhon C, Buecher B, Pierga JY, Bidard FC.

Ann Oncol. 2018 May 1;29(5):1094-1096. doi: 10.1093/annonc/mdy111. No abstract available.

PMID:
29635453
8.

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.

Decraene C, Silveira AB, Bidard FC, Vallée A, Michel M, Melaabi S, Vincent-Salomon A, Saliou A, Houy A, Milder M, Lantz O, Ychou M, Denis MG, Pierga JY, Stern MH, Proudhon C.

Clin Chem. 2018 Feb;64(2):317-328. doi: 10.1373/clinchem.2017.272518. Epub 2017 Nov 9.

9.

Quantifying HER-2 expression on circulating tumor cells by ACCEPT.

Zeune L, van Dalum G, Decraene C, Proudhon C, Fehm T, Neubauer H, Rack B, Alunni-Fabbroni M, Terstappen LWMM, van Gils SA, Brune C.

PLoS One. 2017 Oct 30;12(10):e0186562. doi: 10.1371/journal.pone.0186562. eCollection 2017.

10.

Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.

Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, Piperno-Neumann S, Bernard V, Baulande S, Bieche I, Pierga JY, Proudhon C, Bidard FC.

Ann Oncol. 2017 Aug 1;28(8):1996-2001. doi: 10.1093/annonc/mdx212.

PMID:
28459943
11.

Circulating tumor cells: clinical validity and utility.

Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY, Bidard FC.

Int J Clin Oncol. 2017 Jun;22(3):421-430. doi: 10.1007/s10147-017-1105-2. Epub 2017 Feb 25. Review.

PMID:
28238187
12.

Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?

Cabel L, Proudhon C, Mariani P, Tzanis D, Beinse G, Bieche I, Pierga JY, Bidard FC.

Eur J Surg Oncol. 2017 May;43(5):949-962. doi: 10.1016/j.ejso.2017.01.010. Epub 2017 Jan 29. Review.

PMID:
28185687
13.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P.

Ann Oncol. 2017 Jan 1;28(1):103-109. doi: 10.1093/annonc/mdw535.

PMID:
28177480
14.

Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, Hego C, Milder M, Cottu P, Sablin MP, Vincent-Salomon A, Lantz O, Stern MH, Proudhon C, Pierga JY.

Clin Chem. 2017 Mar;63(3):691-699. doi: 10.1373/clinchem.2016.262337. Epub 2017 Jan 10.

15.

International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant.

Whale AS, Devonshire AS, Karlin-Neumann G, Regan J, Javier L, Cowen S, Fernandez-Gonzalez A, Jones GM, Redshaw N, Beck J, Berger AW, Combaret V, Dahl Kjersgaard N, Davis L, Fina F, Forshew T, Fredslund Andersen R, Galbiati S, González Hernández Á, Haynes CA, Janku F, Lacave R, Lee J, Mistry V, Pender A, Pradines A, Proudhon C, Saal LH, Stieglitz E, Ulrich B, Foy CA, Parkes H, Tzonev S, Huggett JF.

Anal Chem. 2017 Feb 7;89(3):1724-1733. doi: 10.1021/acs.analchem.6b03980. Epub 2017 Jan 18.

PMID:
27935690
16.

Identification of multi-loci hubs from 4C-seq demonstrates the functional importance of simultaneous interactions.

Jiang T, Raviram R, Snetkova V, Rocha PP, Proudhon C, Badri S, Bonneau R, Skok JA, Kluger Y.

Nucleic Acids Res. 2016 Oct 14;44(18):8714-8725. Epub 2016 Jul 20.

17.

Active and Inactive Enhancers Cooperate to Exert Localized and Long-Range Control of Gene Regulation.

Proudhon C, Snetkova V, Raviram R, Lobry C, Badri S, Jiang T, Hao B, Trimarchi T, Kluger Y, Aifantis I, Bonneau R, Skok JA.

Cell Rep. 2016 Jun 7;15(10):2159-2169. doi: 10.1016/j.celrep.2016.04.087. Epub 2016 May 26.

18.

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A.

Ann Oncol. 2016 May;27(5):812-8. doi: 10.1093/annonc/mdw067. Epub 2016 Feb 18.

PMID:
27052658
19.

4C-ker: A Method to Reproducibly Identify Genome-Wide Interactions Captured by 4C-Seq Experiments.

Raviram R, Rocha PP, Müller CL, Miraldi ER, Badri S, Fu Y, Swanzey E, Proudhon C, Snetkova V, Bonneau R, Skok JA.

PLoS Comput Biol. 2016 Mar 3;12(3):e1004780. doi: 10.1371/journal.pcbi.1004780. eCollection 2016 Mar.

20.

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.

Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern MH, Lantz O, Proudhon C, Pierga JY, Bidard FC.

Mol Oncol. 2016 Mar;10(3):481-93. doi: 10.1016/j.molonc.2016.01.006. Epub 2016 Jan 22. Review.

21.

Circulating tumor cells in breast cancer.

Bidard FC, Proudhon C, Pierga JY.

Mol Oncol. 2016 Mar;10(3):418-30. doi: 10.1016/j.molonc.2016.01.001. Epub 2016 Jan 12. Review.

22.

Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.

Saliou A, Bidard FC, Lantz O, Stern MH, Vincent-Salomon A, Proudhon C, Pierga JY.

Expert Rev Mol Diagn. 2016;16(1):39-50. doi: 10.1586/14737159.2016.1121100. Epub 2015 Dec 9. Review.

PMID:
26568208
23.

Long-Range Regulation of V(D)J Recombination.

Proudhon C, Hao B, Raviram R, Chaumeil J, Skok JA.

Adv Immunol. 2015;128:123-82. doi: 10.1016/bs.ai.2015.07.003. Epub 2015 Aug 20. Review.

24.

Protection against de novo methylation is instrumental in maintaining parent-of-origin methylation inherited from the gametes.

Proudhon C, Duffié R, Ajjan S, Cowley M, Iranzo J, Carbajosa G, Saadeh H, Holland ML, Oakey RJ, Rakyan VK, Schulz R, Bourc'his D.

Mol Cell. 2012 Sep 28;47(6):909-20. doi: 10.1016/j.molcel.2012.07.010. Epub 2012 Aug 16.

25.

The parental non-equivalence of imprinting control regions during mammalian development and evolution.

Schulz R, Proudhon C, Bestor TH, Woodfine K, Lin CS, Lin SP, Prissette M, Oakey RJ, Bourc'his D.

PLoS Genet. 2010 Nov 18;6(11):e1001214. doi: 10.1371/journal.pgen.1001214.

26.

Identification and resolution of artifacts in the interpretation of imprinted gene expression.

Proudhon C, Bourc'his D.

Brief Funct Genomics. 2010 Dec;9(5-6):374-84. doi: 10.1093/bfgp/elq020. Epub 2010 Sep 8.

27.

[Evolution of genomic imprinting in mammals: what a zoo!].

Proudhon C, Bourc'his D.

Med Sci (Paris). 2010 May;26(5):497-503. doi: 10.1051/medsci/2010265497. Review. French.

28.

Sexual dimorphism in parental imprint ontogeny and contribution to embryonic development.

Bourc'his D, Proudhon C.

Mol Cell Endocrinol. 2008 Jan 30;282(1-2):87-94. doi: 10.1016/j.mce.2007.11.025. Epub 2007 Nov 29. Review.

PMID:
18178305

Supplemental Content

Loading ...
Support Center